<Disease><Name>G(M2)-GANGLIOSIDOSIS: VARIANT 0, SANDHOFF DISEASE</Name><Synonym>SANDHOFF DISEASE; G(M2)-GANGLIOSIDOSIS WITH HEXOSAMINIDASE A AND B DEFICIENCY</Synonym><OMIM><Number>268800</Number><URL>http://omim.org/entry/268800</URL></OMIM><Orphanet><Number>796</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=796</URL></Orphanet><Protein><Number>beta-hexosaminidase subunit beta</Number><URL>http://www.uniprot.org/uniprot/P07686</URL></Protein><ExPASy><Number /><URL /></ExPASy><Gene>5q13.3</Gene><ICD>E75.0</ICD><Summary>rare (1:300000);autosomal recessive ;mutation in the beta subunit of hexosaminidase;3 types: ;- infantile, acute form (classical Sandhoff disease) ;- subacute form ;- chronic form</Summary><Symptoms><symtomp><id>1942</id><symptom>ataxia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2211</id><symptom>blindness, visual loss, visual impairment</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1966</id><symptom>cerebellar atrophy or hypoplasia</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1733</id><symptom>cherry-red spot on retinal macula</symptom><category>EYES</category></symtomp><symtomp><id>2117</id><symptom>CT, brain, abnormalities [-] / CT, kraniell, abnormal </symptom><category>LABORATORY FINDINGS</category></symtomp><symtomp><id>2302</id><symptom>dysostosis multiplex</symptom><category>SKELATAL DEFECT</category></symtomp><symtomp><id>2423</id><symptom>early death</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1994</id><symptom>hepatomegaly (large liver)</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>1897</id><symptom>hypotonia</symptom><category>MUSCLES | NERVOUS SYSTEM</category></symtomp><symtomp><id>3843</id><symptom>leukodystrophy</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>1887</id><symptom>macrocephaly (large calvaria, &gt;2 SD for age)</symptom><category>HEAD</category></symtomp><symtomp><id>2424</id><symptom>mental retardation</symptom><category>NERVOUS SYSTEM</category></symtomp><symtomp><id>2213</id><symptom>MRI, brain, abnormalities [-]</symptom><category>LABORATORY FINDINGS | NERVOUS SYSTEM</category></symtomp><symtomp><id>1915</id><symptom>onset, adulthood / adoulthood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>1739</id><symptom>optic atrophy</symptom><category>EYES | NERVOUS SYSTEM</category></symtomp><symtomp><id>1943</id><symptom>seizures</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp><symtomp><id>1974</id><symptom>spastic diplegia/quadriplegia/tetraplegia</symptom><category>NERVOUS SYSTEM | NERVOUS SYSTEM</category></symtomp></Symptoms><Metabolites><metabolite><id>924</id><name>beta-Hexosaminidase</name><specimen>serum</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>925</id><name>beta-Hexosaminidase</name><specimen>leucocytes</specimen><value>decreased</value><min>    </min><max>100.00</max><unit>% activity</unit><age>no data</age><method /><comment /></metabolite><metabolite><id>965</id><name>Oligosaccharides</name><specimen>urine</specimen><value>abnormal</value><min>    </min><max>    </max><unit>not detectable</unit><age>no data</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>7955</id><title>Patient and caregiver perspectives on burden of disease manifestations in late-onset Tay-Sachs and Sandhoff diseases</title><author>Lyn N,</author><journal>Orphanet J Rare Dis</journal><year>2020</year><book /><volume>15</volume><number>1</number><pages>92</pages><co_aut>et al.</co_aut></literature><literature><id>4503</id><title>The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy</title><author>Regier DS,</author><journal>Pediatr Endocrinol Rev Suppl</journal><year>2016</year><book /><volume>13</volume><number>1</number><pages>663-673</pages><co_aut>et al.</co_aut></literature><literature><id>4508</id><title>Chaperone therapy for GM2 gangliosidosis: effects of pyrimethamine on &#946;-hexosaminidase activity in Sandhoff fibroblasts</title><author>Chiricozzi E,</author><journal>Mol Neurobiol</journal><year>2014</year><book /><volume>50</volume><number>1</number><pages>159-167</pages><co_aut>et al.</co_aut></literature><literature><id>4509</id><title>Juvenile Sandhoff disease--nine new cases and a review of the literature</title><author>Hendriksz CJ,</author><journal>J Inherit Metab Dis</journal><year>2004</year><book /><volume>27</volume><number>2</number><pages>241-249</pages><co_aut>et al.</co_aut></literature><literature><id>934</id><title>Progressive cerebellar ataxia in juvenile GM2-gangliosidosis type Sandhoff</title><author>Beck M</author><journal>Eur J Pediatr</journal><year>1997</year><book /><volume>0</volume><number>0</number><pages>866-867</pages><co_aut>Sieber N, Goebel HH</co_aut></literature><literature><id>156</id><title>The GM2 gangliosidoses</title><author>Gravel RA</author><journal>The metabolic and molecular bases of inherited disease, 7/e; Editors: C.R.Scriver, A.L.Beaudet, W.S.Sly, D.Valle; McGraw-Hill Inc.</journal><year>1995</year><book /><volume>2</volume><number>92</number><pages>2839-2879</pages><co_aut>Clarke JTR, Kaback MM, Mahuran D, Sandhoff K, Suzuki K</co_aut></literature><literature><id>259</id><title>Thalamic hyperdensity -- is it a diagnostic marker for Sandhoff disease ?</title><author>Caliskan M</author><journal>Brain Dev</journal><year>1993</year><book /><volume>15</volume><number>5</number><pages>387-388</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>